Texas Biotechnology Corporation

Texas Heart Institute

Encysive Pharmaceuticals, Inc.

Aviara Pharmaceuticals, Inc.

Pfizer Corporation

Texas Children's Hospital

Robert V Market

Ronald J Biediger

Chengde Wu

Jamal M Kassir

George W Holland

Jie Chen

Wen Li

Ian Leslie Scott

Michael M Savage

Brandon M Young

Bore G Raju

Peter Vanderslice

Daxin Gao

Vanessa O Grabbe

Shuqun Lin

E Radford Decker

Michele A Benish

Timothy P Kogan

Karin M Keller

Brian Dupre

Jian Li

Qi Chen

William C Gundlach, Iv

Ananth V Annapragada

James T Willerson

Eric A Tanifum

Keith Allen Monk

Darren G Woodside

Vincent A Boyd

Pedro Lory

Reginald L Tennyson

Timothy P Kogan, Deceased

Noel Nguyen

Eric C Anderson

Thomas P Thrash

Lindsay Bonner Hardy

Richard Dixon

Linda K Hamaker

Timothy P Di Kogan

Ian L Scott

Raju G Bore

Radford E Decker

Iv William C Gundlach

Iv C William Gundlach

Eric Tanifum

Reginald Tennyson

Keith A Monk

C William Gundlach

Disclosed herein is a composition comprising a plurality of liposomes having an average diameter of less than 400 nanometers, wherein the plurality of liposomes comprise: a first lipid or phospholipid; a second lipid or phospholipid which is derivatized with a polymer; and a sterically bulky excipient capable of stabilizing the liposomes; a third lipid or phospholipid derivatized with a polymer terminated with an integrin targeting component; DSPE or a fourth lipid or phospholipid derivatized with a group binding a contrast enhancing agent wherein the plurality of liposomes optionally encapsulates a payload component consisting of one or more bioactive agents.

Targeting nanoparticles

Provided herein are compounds and pharmaceutical compositions of formula I where R, R, R, R, Rand Rare as described herein. Also provided pharmaceutically acceptable salts or stereoisomers of these compounds. In addition methods are provided for inhibiting the binding of an integrin to treat various pathophysiological conditions.

Propionic acid derivatives and methods of use thereof

Provided herein are methods for antagonizing the action of an &#x3b1;4-integrin to treat various pathophysiological conditions utilizing pharmaceutical compositions of compounds or pharmaceutically acceptable salts or stereoisomer(s) thereof of formula I where R, R, R, R, R, X and Rare as described herein.

A method of enhancing binding of cells to an integrin-binding ligand comprises treating integrin-expressing cells in vitro with an agonist of integrin, wherein the integrin is selected from the group consisting of &#x3b1;4&#x3b2;1, &#x3b1;5&#x3b2;1, &#x3b1;4&#x3b2;7, &#x3b1;v&#x3b2;3 and &#x3b1;L&#x3b2;2, and contacting the treated cells with an integrin-binding ligand; integrin agonist compounds having the general formula I; methods of treating integrin-expressing cells with such agonists to enhance binding; and therapeutic methods comprising administering agonist-treated cells or agonist compounds to a mammal.

Agonists that enhance binding of integrin-expressing cells to integrin receptors

Provided herein are compounds and pharmaceutical compositions of formula I where R, R, R, R, R, X and Rare as described herein. Also provided pharmaceutically acceptable salts or stereoisomer(s) of these compounds. In addition methods are provided for antagonizing the action of an &#x3b1;4-integrin to treat various pathophysiological conditions.

Agonists that enhanced binding of integrin-expressing cells to integrin receptors

Provided are compounds that are modulators of CCR9 receptor activity, compositions containing the compounds and methods of use of the compounds and compositions. In certain embodiments, provided are methods for treating or ameliorating diseases associated with modulation of CCR9 receptor activity.

Modulators of CCR9 receptor and methods of use thereof

A method for the inhibition of the binding of &#x3b1;&#x3b2;integrin to its receptors, for example VCAM-1 (vascular cell adhesion molecule-1) and fibronectin; compounds that inhibit this binding; pharmaceutically active compositions comprising such compounds; and to the use of such compounds either a above, or in formulations for the control or prevention of diseases states in which &#x3b1;&#x3b2;is involved.

Carboxylic acid derivatives that inhibit the binding of integrins to their receptors

The present invention relates to urotensin II receptor antagonists, CCR-9 antagonists, pharmaceutical compositions containing them and their use.

Phenylenediamine urotensin-II receptor antagonists and CCR-9 antagonists

Phenylenediamine Urotensin-II receptor antagonists and CCR-9 antagonists

Propanoic acid derivatives that inhibit the binding of integrins to their receptors

A method for the inhibition of the binding of &agr;,&bgr;,integrin to its receptors, for example VCAM-1 (vascular cell adhesion molecule-1) and fibronectin; compounds that inhibit this binding; pharmaceutically active compositions thereof; and the use of the compounds either as above, or in formulations for the control or prevention of diseases states in which &agr;,&bgr;,is involved.

Compounds that inhibit the binding of integrins to their receptors

Growing community of inventors

Pearland, TX, United States of America

Robert V Market